233 related articles for article (PubMed ID: 17890427)
1. A discordance in rosiglitazone mediated insulin sensitization and skeletal muscle mitochondrial content/activity in Type 2 diabetes mellitus.
Pagel-Langenickel I; Schwartz DR; Arena RA; Minerbi DC; Johnson DT; Waclawiw MA; Cannon RO; Balaban RS; Tripodi DJ; Sack MN
Am J Physiol Heart Circ Physiol; 2007 Nov; 293(5):H2659-66. PubMed ID: 17890427
[TBL] [Abstract][Full Text] [Related]
2. Improved skeletal muscle oxidative enzyme activity and restoration of PGC-1 alpha and PPAR beta/delta gene expression upon rosiglitazone treatment in obese patients with type 2 diabetes mellitus.
Mensink M; Hesselink MK; Russell AP; Schaart G; Sels JP; Schrauwen P
Int J Obes (Lond); 2007 Aug; 31(8):1302-10. PubMed ID: 17310221
[TBL] [Abstract][Full Text] [Related]
3. Opposite effects of pioglitazone and rosiglitazone on mitochondrial respiration in skeletal muscle of patients with type 2 diabetes.
Rabøl R; Boushel R; Almdal T; Hansen CN; Ploug T; Haugaard SB; Prats C; Madsbad S; Dela F
Diabetes Obes Metab; 2010 Sep; 12(9):806-14. PubMed ID: 20649633
[TBL] [Abstract][Full Text] [Related]
4. The insulin-sensitizing effect of rosiglitazone in type 2 diabetes mellitus patients does not require improved in vivo muscle mitochondrial function.
Schrauwen-Hinderling VB; Mensink M; Hesselink MK; Sels JP; Kooi ME; Schrauwen P
J Clin Endocrinol Metab; 2008 Jul; 93(7):2917-21. PubMed ID: 18460571
[TBL] [Abstract][Full Text] [Related]
5. Rosiglitazone improves exercise capacity in individuals with type 2 diabetes.
Regensteiner JG; Bauer TA; Reusch JE
Diabetes Care; 2005 Dec; 28(12):2877-83. PubMed ID: 16306548
[TBL] [Abstract][Full Text] [Related]
6. Reduced skeletal muscle uncoupling protein-3 content in prediabetic subjects and type 2 diabetic patients: restoration by rosiglitazone treatment.
Schrauwen P; Mensink M; Schaart G; Moonen-Kornips E; Sels JP; Blaak EE; Russell AP; Hesselink MK
J Clin Endocrinol Metab; 2006 Apr; 91(4):1520-5. PubMed ID: 16384852
[TBL] [Abstract][Full Text] [Related]
7. Rosiglitazone but not metformin enhances insulin- and exercise-stimulated skeletal muscle glucose uptake in patients with newly diagnosed type 2 diabetes.
Hällsten K; Virtanen KA; Lönnqvist F; Sipilä H; Oksanen A; Viljanen T; Rönnemaa T; Viikari J; Knuuti J; Nuutila P
Diabetes; 2002 Dec; 51(12):3479-85. PubMed ID: 12453903
[TBL] [Abstract][Full Text] [Related]
8. Effects of physical activity and weight loss on skeletal muscle mitochondria and relationship with glucose control in type 2 diabetes.
Toledo FG; Menshikova EV; Ritov VB; Azuma K; Radikova Z; DeLany J; Kelley DE
Diabetes; 2007 Aug; 56(8):2142-7. PubMed ID: 17536063
[TBL] [Abstract][Full Text] [Related]
9. Rosiglitazone improves downstream insulin receptor signaling in type 2 diabetic patients.
Miyazaki Y; He H; Mandarino LJ; DeFronzo RA
Diabetes; 2003 Aug; 52(8):1943-50. PubMed ID: 12882909
[TBL] [Abstract][Full Text] [Related]
10. FTO is increased in muscle during type 2 diabetes, and its overexpression in myotubes alters insulin signaling, enhances lipogenesis and ROS production, and induces mitochondrial dysfunction.
Bravard A; Lefai E; Meugnier E; Pesenti S; Disse E; Vouillarmet J; Peretti N; Rabasa-Lhoret R; Laville M; Vidal H; Rieusset J
Diabetes; 2011 Jan; 60(1):258-68. PubMed ID: 20943749
[TBL] [Abstract][Full Text] [Related]
11. Activation of protein kinase C-zeta by insulin and phosphatidylinositol-3,4,5-(PO4)3 is defective in muscle in type 2 diabetes and impaired glucose tolerance: amelioration by rosiglitazone and exercise.
Beeson M; Sajan MP; Dizon M; Grebenev D; Gomez-Daspet J; Miura A; Kanoh Y; Powe J; Bandyopadhyay G; Standaert ML; Farese RV
Diabetes; 2003 Aug; 52(8):1926-34. PubMed ID: 12882907
[TBL] [Abstract][Full Text] [Related]
12. Oxidative stress in skeletal muscle impairs mitochondrial respiration and limits exercise capacity in type 2 diabetic mice.
Yokota T; Kinugawa S; Hirabayashi K; Matsushima S; Inoue N; Ohta Y; Hamaguchi S; Sobirin MA; Ono T; Suga T; Kuroda S; Tanaka S; Terasaki F; Okita K; Tsutsui H
Am J Physiol Heart Circ Physiol; 2009 Sep; 297(3):H1069-77. PubMed ID: 19617406
[TBL] [Abstract][Full Text] [Related]
13. Human skeletal muscle mitochondrial dynamics in relation to oxidative capacity and insulin sensitivity.
Houzelle A; Jörgensen JA; Schaart G; Daemen S; van Polanen N; Fealy CE; Hesselink MKC; Schrauwen P; Hoeks J
Diabetologia; 2021 Feb; 64(2):424-436. PubMed ID: 33258025
[TBL] [Abstract][Full Text] [Related]
14. Pioglitazone ameliorates the lowered exercise capacity and impaired mitochondrial function of the skeletal muscle in type 2 diabetic mice.
Takada S; Hirabayashi K; Kinugawa S; Yokota T; Matsushima S; Suga T; Kadoguchi T; Fukushima A; Homma T; Mizushima W; Masaki Y; Furihata T; Katsuyama R; Okita K; Tsutsui H
Eur J Pharmacol; 2014 Oct; 740():690-6. PubMed ID: 24964389
[TBL] [Abstract][Full Text] [Related]
15. Thiazolidinediones upregulate impaired fatty acid uptake in skeletal muscle of type 2 diabetic subjects.
Wilmsen HM; Ciaraldi TP; Carter L; Reehman N; Mudaliar SR; Henry RR
Am J Physiol Endocrinol Metab; 2003 Aug; 285(2):E354-62. PubMed ID: 12700163
[TBL] [Abstract][Full Text] [Related]
16. v- and t-SNARE protein expression in models of insulin resistance: normalization of glycemia by rosiglitazone treatment corrects overexpression of cellubrevin, vesicle-associated membrane protein-2, and syntaxin 4 in skeletal muscle of Zucker diabetic fatty rats.
Maier VH; Melvin DR; Lister CA; Chapman H; Gould GW; Murphy GJ
Diabetes; 2000 Apr; 49(4):618-25. PubMed ID: 10871200
[TBL] [Abstract][Full Text] [Related]
17. Increased malonyl-CoA levels in muscle from obese and type 2 diabetic subjects lead to decreased fatty acid oxidation and increased lipogenesis; thiazolidinedione treatment reverses these defects.
Bandyopadhyay GK; Yu JG; Ofrecio J; Olefsky JM
Diabetes; 2006 Aug; 55(8):2277-85. PubMed ID: 16873691
[TBL] [Abstract][Full Text] [Related]
18. Changes in skeletal muscle mitochondria in response to the development of type 2 diabetes or prevention by daily wheel running in hyperphagic OLETF rats.
Rector RS; Uptergrove GM; Borengasser SJ; Mikus CR; Morris EM; Naples SP; Laye MJ; Laughlin MH; Booth FW; Ibdah JA; Thyfault JP
Am J Physiol Endocrinol Metab; 2010 Jun; 298(6):E1179-87. PubMed ID: 20233940
[TBL] [Abstract][Full Text] [Related]
19. Pioglitazone-induced improvements in insulin sensitivity occur without concomitant changes in muscle mitochondrial function.
Bajpeyi S; Pasarica M; Conley KE; Newcomer BR; Jubrias SA; Gamboa C; Murray K; Sereda O; Sparks LM; Smith SR
Metabolism; 2017 Apr; 69():24-32. PubMed ID: 28285649
[TBL] [Abstract][Full Text] [Related]
20. Mitochondrial oxidative function and type 2 diabetes.
Rabøl R; Boushel R; Dela F
Appl Physiol Nutr Metab; 2006 Dec; 31(6):675-83. PubMed ID: 17213881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
